FIG. 1




Refractory and Relapsed and Refractory Multiple Myeloma patients
Stratification:
- age (< 75 y old vs. ≥ 75 y old)
- number of prior lines (2 or 3 vs. > 3)
RANDOMIZATION
1:1
IPd arm (154 patients)
Isatuximab: 10 mg/kg weekly first cycle, then Q2W
Pomalidomide 4 mg/day from D1 to D21
Dexamethasone 40 mg (20 mg if ≥ 75 y) D1, D8, 15 and D22
Cycle duration = 28 days
Pd arm (153 patients)
Pomalidomide 4 mg/day from D1 to D21
Dexamethasone 40 mg (20 mg if ≥ 75 y) D1, D8, 15 and D22
Cycle duration = 28 days
D=study day, y=years, IPd=isatuximab, pomalidomide, dexamethasone, PD=pomalidomide, dexamethasone

FIG. 2




Median follow-up time = 11.60 months

PFS: Progression-free survival, IRC: Independent Response Committee

Logrank p value: Stratified on age (<75 years versus >=75 years) and number of previous lines of therapy (2 or 3 versus > 3) according to IRT

FIG. 3




Median follow-up time = 11.60 months

PFS: Progression-free survival

Logrank p value: Stratified on age (<75 years versus >=75 years) and number of previous lines of therapy (2 or 3 versus > 3) according to IRT.

FIG. 4



Logrank p value: Stratified on age (<75 years versus >=75 years) and number of previous lines of therapy (2 or 3 versus > 3) according to IRT. Significance level is set to 0.0017 using the O'Brien-Fleming alpha spending function.



Subgroup
Number of patients
Isa-Pd
Pd
Hazard ratio (95% CI)
Age
<65 years 54 70 0.66 (0.40-1.07)
65-75 years 68 54 0.64 (0.39-1.06)
≥75 years 32 29 0.48 (0.24-0.95)
Baseline eGFR (MDRD)
≥60 mL/min/1.73m2 87 96 0.58 (0.38-0.88)
<60 mL/min/1.73m2 55 49 0.50 (0.30-0.85)
No. of prior lines of therapy
2-3 102 101 0.59 (0.40-0.88)
>3 52 52 0.59 (0.36-0.98)
Previous autologous stem cell transplant
Yes 83 90 0.60 (0.40-0.90)
No 71 63 0.62 (0.38-1.00)
Cytogenetic risk
High 24 36 0.66 (0.33-1.28)
Standard 103 78 0.62 (0.42-0.93)
Refractory to lenalidomide
Yes 144 140 0.59 (0.43-0.82)
No 10 13 0.18 (0.02-1.49)
Refractory to a proteasome inhibitor
Yes 118 115 0.58 (0.41-0.82)
No 36 38 0.67 (0.35-1.28)
Refractory to lenalidomide and a proteasome inhibitor
Yes 111 107 0.58 (0.40-0.84)
No 43 46 0.60 (0.33-1.11)
Refractory to lenalidomide at last previous line
Yes 93 88 0.50 (0.34-0.76)
No 61 65 0.77 (0.47-1.25)
R-ISS disease stage at study entry
I 39 31 0.58 (0.28-1.21)
II 99 98 0.59 (0.40-0.87)
III 16 24 0.61 (0.28-1.31)
0.0 0.5 1.0 1.5 2.0
Favors Isa-pd
Favors pd
CI, confidence interval; dex, dexamethasone; eGFR, estimated glomerular filtration rate; Isa, isatuximab; MDRD, Modification of Diet in Renal Disease study equation; PFS,Progression-free survival; (R-)ISS, (Revised) International staging System

FIG. 5

FIG. 6A



MRD negative
MRD positive and VGPR or better
PR
Less than PR
Kaplan-Meier estimate
Time (months)
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0
2
4
6
8
10
12
14
16
18
Less than PR
PR
MRD+ VGPR or better
MRD-
Censor

FIG. 6B




MRD negative
MRD positive and VGPR or better
PR
Less than PR
Kaplan-Meier estimate
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0
2
4
6
8
10
12
14
16
18
Time (months)
Less than PR
PR
MRD+ VGPR or better
MRD-
Censor

FIG. 7



CRenal, complete renal response; d, dexamethasone; Isa, isatuximab; P, pomalidomide